

BD SurePath™ Liquid-based Pap Test

Keeping you ahead of the curve in cervical cancer screening



Answering the need for cytology accuracy

A lack of standardization in sampling and slide preparation in cytology increases the probability of unsatisfactory results and diminishes the probability of finding abnormal cells, resulting in ambiguous or inaccurate diagnoses.¹⁻³ Liquid-based cytology significantly enhances specimen quality, detection of cervical lesions, and cost-effectiveness.²

The BD SurePath™ Liquid-based Pap Test offers simple cell collection, unique sample processing and definitive results for optimised diagnosis and improved patient care.³⁻⁷



Reliable sample collection


- The head of the collection device is deposited directly into the BD SurePath™ Collection Vial, so 100% of the collected cells are sent to the laboratory for analysis.^{3,4,8}




Unique and standardised sample processing

- A proprietary cell enrichment process eliminates blood, inflammatory cells, mucus and other debris, so only the most diagnostically relevant material is presented on the slide, offering a clear background.^{5,6}
- Automated slide preparation with on-board staining results in a 13 mm deposition area and uniform distribution of the cells in a thin layer.⁹


Microscopy images of cervical cells obtained using BD SurePath™ Liquid-based Pap Test




ASCUS



LSIL



HSIL



Cancer



Accurate and definitive results that enhance patient care

- The unsatisfactory reports are reduced to almost 0%,⁷ which may avoid patient call-backs and lost follow-up.¹⁰
- Overall cervical disease detection is increased compared to conventional cytology and other liquid-based cytology devices,^{3,7} leading to fewer cases of cervical cancer in the follow-up period.¹¹
- Compared to conventional cytology, BD SurePath™ Liquid-based Pap Test resulted in:⁷
 - 58.4% less unsatisfactory reports
 - 28.9% reduction in ASCUS/LSIL+ ratio
 - 64.4% increase in HSIL+ detection
 - 107.2% increase in LSIL+ detection



Flexibility to run both cytology and HPV testing with one sample

- The BD SurePath™ Collection Vial is CE-marked for most CE-marked HPV assays, including the BD Onclarity™ HPV Assay, and FDA-approved for the Roche Cobas® HPV Assay and the BD Onclarity™ HPV Assay.



The BD SurePath™ Liquid-based Pap Test is your trusted partner in cytology testing, from sample collection to result reporting.



Flexible cytology testing automation from sample to result

The **BD SurePath™ Liquid-based Pap Test** can be processed according to the throughput and the automation levels needed, ensuring efficiency, precision, and full traceability across instruments from sample to results.

Sample preparation, including cell enrichment



BD PrepMate™ Automated Accessory

For low- to mid-volume laboratories

Compact design delivering precise sample transfer^{12,13}



BD Totalys™ MultiProcessor

For high-volume laboratories

Flexibility to meet evolving screening algorithms

Automates the BD SurePath™ Liquid-based Pap Test cell enrichment process for cytology testing and prepares aliquots for molecular testing¹⁴

Slide preparation and staining



BD Totalys™ SlidePrep

For mid- to high-volume laboratories

Efficiency and confidence in slide processing⁹

Automates slide preparation and staining and processes BD SurePath™ and non-gynaecological samples.⁹

Slide imaging



BD FocalPoint™ GS Imaging System

For high-volume laboratories

Greater efficiency through enhanced slide imaging¹⁵

Improves cervical cancer detection and screening efficiency by ranking slides and prioritizing review of locations of interest on BD SurePath™ Liquid-based Pap Test and Conventional preparations.^{15,16}

BD is your partner for continuous learning, offering a wide range of high-quality trainings

- **BD SurePath™ Quality Assurance Program** to help you monitor the diagnostic performance of your laboratory
- **BD SurePath™ Case Of The Month Program** to discover specific morphology cases
- **BD SurePath™ Morphology Webinars**, a series of webinars to make your transition to cervical cancer screening with SurePath™ easy and seamless
- Meet with our experts during the **BD 'MEET THE EXPERT' webinars** in which different morphology topics are discussed

Acting as a single source provider for both HPV and cytology testing, BD's cervical cancer screening portfolio offers integrated solutions from sample to result, for every laboratory setting and any cervical cancer screening paradigm.

References: 1. Gibb RK and Martens MG. Rev Obstet Gynecol. 2011;4(Suppl 1):S2–S11. 2. Hoda RS et al. Diagn Cytopathol. 2013;41(3):257–78. 3. Nance KV. Diagn Cytopathol. 2007;35(3):148–53. 4. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–74. 5. Sweeney BJ et al. Cancer Cytopathol. 2006;108(1):27–31. 6. Kenyon S et al. Cancer Cytopathol. 2010;118(5):244–9. 7. Fremont-Smith M et al. Cancer. 2004;102(5):269–79. 8. BD SurePath™ Collection Vial Package Insert (500017013). 9. BD Totalys™ SlidePrep Instrument User's Manual (500005570). 10. Ransdell JS et al. Cancer Cytopathol. 1997;81(3):139–43. 11. Rozemeijer K et al. BMJ. 2017;356:j504. 12. Rabaan AA et al. J Med Microbiol. 2018;67(5):676–80. 13. BD PrepMate™ Automated Accessory Operator's Manual (500005571). 14. BD Totalys™ MultiProcessor User's Manual (8089991). 15. BD FocalPoint™ GS Imaging System US Product Insert (500040544). 16. BD FocalPoint™ Slide Profiler Product Insert (7790419402).

BD - Europe, Terre-Bonne Park - A4, Route de Crassier - 17, 1262 Eysins, Switzerland

bd.com



BD SurePath™, BD Onclarity™ HPV Assay, BD PrepMate™, BD Totalys™ Multiprocessor, BD Totalys™ SlidePrep and BD FocalPoint™ GS Imaging System are bearing a CE mark. BD, the BD logo, BD SurePath™, BD Onclarity™, BD PrepMate™, BD Totalys™, BD Totalys™, BD FocalPoint™ are trademarks of Becton, Dickinson and Company. All other trademarks are from their respective owners. © 2022 BD. All rights reserved. BD-60229

